港股異動丨華領醫藥三日累跌40% 瑞銀下調目標價
格隆匯11月14日丨華領醫藥-B(02552.HK)再度大跌近6%,該股已經連跌5個交易日,近3個交易日累跌40%,暫報4.09港元,成交1008萬港元,總市值43億港元。

華領醫藥日前公佈旗下糖尿病治療的Dorzagliatin單藥療法III期臨牀研究(HMM0301)24周研究結果,數據表現不俗但股價卻應聲下跌。
瑞銀近日發佈研報稱,對研究結果感到滿意,認為公司手持1.8億美元現金流,估值約6億美元屬吸引,但指出華領或需要向投資者作進一步澄清,以免外界對研究結果產生誤會,又指流動性不足引發股價波動亦是該公司面對的主要風險之一。
考慮到產品商業化時間表延至明年底,預期Dorzagliatin要到2021年才可銷售,該行下調對華領醫藥目標價由13.4港元降至12.1港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.